Skip Navigation


JAC Advance Access originally published online on March 6, 2009
Journal of Antimicrobial Chemotherapy 2009 63(5):988-991; doi:10.1093/jac/dkp044
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
63/5/988    most recent
dkp044v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vogel, M.
Right arrow Articles by Reichel, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogel, M.
Right arrow Articles by Reichel, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals

Martin Vogel1, Norbert Bertram2, Jan-Christian Wasmuth1, Christoph Wyen3, Esther Voigt1, Carolynne Schwarze-Zander1, Thomas Sudhop4, Gerd Fätkenheuer3, Jürgen K. Rockstroh1,* and Christoph Reichel1

1 Department of Internal Medicine I, Bonn University, Bonn, Germany 2 Laboratory for Toxicology and Analytics, Königswinter, Germany 3 Department of Internal Medicine I, Cologne University, Cologne, Germany 4 Federal Institute for Drugs and Medical Devices, Bonn, Germany

Received 7 November 2008; returned 16 December 2008; revised 27 January 2009; accepted 30 January 2009

* Corresponding author. Tel: +49-228-287-16558; Fax: +49-228-287-15034; E-mail: juergen.rockstroh{at}ukb.uni-bonn.de

Objectives: An increased risk of drug-related liver injury has been repeatedly reported in individuals infected with hepatitis C virus (HCV) receiving the antiretroviral drug nevirapine. This study was undertaken to assess the differences in the pharmacokinetics of nevirapine between patients with HIV/HCV coinfection and HIV infection that could explain higher rates of hepatotoxicity.

Methods: A 12 h pharmacokinetic analysis was performed in 18 patients: 7 HIV/HCV-coinfected and 11 HIV-monoinfected. Advanced liver disease was an exclusion criterion in order to assess the impact of chronic HCV infection alone.

Results: Comparing the two groups, no difference was observed between minimum and maximum drug levels or total drug exposure in terms of area under the curve.

Conclusions: Hepatitis C coinfection does not alter the pharmacokinetics of nevirapine in patients with preserved liver function.

Keywords: AUC , therapeutic drug monitoring , hepatitis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.